Holen Sie sich die Stockscreener-App
1.77
2.91%
0.05
Handel nachbörslich:
1.77
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by Two Sigma Investments LP - MarketBeat
Millennium Management LLC Has $3.49 Million Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Two Sigma Advisers LP Increases Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World
Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia
1 Stock Down 97% That Could Double, According to Wall Street - The Globe and Mail
Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World
Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT S - GuruFocus
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus
Stifel Financial Corp Sells 287,718 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Balyasny Asset Management L.P. Grows Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by StockNews.com - Defense World
Editas Medicine: A Cautionary Tale for Investors - AOL.com
Raymond James Financial Inc. Invests $303,000 in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Robert W. Baird Has Lowered Expectations for Editas Medicine (NASDAQ:EDIT) Stock Price - MarketBeat
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - Pharma Voice
Robert W. Baird Issues Pessimistic Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - Defense World
Editas Medicine Reports Q1 2025 Progress and Financials - TipRanks
Editas Medicine: A Cautionary Tale For Investors - Barchart.com
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Editas Medicine to Present in vivo HSC Delivery, Editing, and Bi - GuruFocus
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - The Manila Times
Editas Medicine to Present in vivo HSC Delivery, Editing, - GlobeNewswire
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the ... - Bluefield Daily Telegraph
Editas optimistic on CRISPR patent outcome after appeal By Investing.com - Investing.com Nigeria
Editas Medicine (EDIT) Advances Gene Editing for Blood Disorders with Promising Results | EDIT Stock News - GuruFocus
Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas' Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting - marketscreener.com
Editas Medicine Reports New In Vivo Data Highlighting the Potent - GuruFocus
Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs - TipRanks
Editas Medicine Unveils Promising Gene Editing Data - TipRanks
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Editas Medicine Reports Promising In Vivo Gene Editing Results for Sickle Cell Disease and Beta Thalassemia at ASGCT Annual Meeting - Nasdaq
Editas Medicine Reports New In Vivo Data Highlighting the - GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - TradingView
Editas Medicine at BofA Securities 2025: In Vivo Gene Editing Focus - Investing.com Canada
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Dimensional Fund Advisors LP - Defense World
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):